SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 5 of 23
Word Count: 1399
Character Count: 8515

Document Content:

subject to substantial risks . You should consider the “Risk Factors” and the “Cautionary Note Regarding Forward-Looking Statements” included and incorporated by reference in this prospectus supplement, including the risk factors incorporated by reference from our filings with the SEC. Nasdaq Capital Market symbol “SNYR” The discussion and table above are based on 11,251,853 shares of common stock outstanding as of December 8, 2025, and excludes the following securities as of that date: ● excludes 1,452,102 shares of common stock issuable upon the exercise of outstanding options at a weighted average exercise price of $3.03 per share; ● excludes 1,052,102 shares of common stock reserved for future issuance pursuant to the Synergy CHC Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”); and ● excludes 156,000 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $8.69 per share. RISK FACTORS

Investing in our securities
is highly speculative and involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully
consider the risk factors we describe in this prospectus supplement and the prospectus and in any related free writing prospectus that
we may authorize to be provided to you or in any report incorporated by reference into this prospectus supplement, including our Annual
Report on Form 10-K for the year ended December 31, 2024, or any Annual Report on Form 10-K or Quarterly Report on Form 10-Q that is incorporated
by reference into this prospectus supplement after the date of this prospectus supplement. Although we discuss key risks in those risk
factor descriptions, additional risks not currently known to us or that we currently deem immaterial also may impair our business. Our
subsequent filings with the SEC may contain amended and updated discussions of significant risks. We cannot predict future risks or estimate
the extent to which they may affect our financial performance.

Risks Related to This Offering

You may experience immediate and substantial dilution as a result
of this offering.

The offering price per share
in this “at the market” offering program may exceed the net tangible book value per share of our common stock. Assuming that
an aggregate of 3,126,373 shares of our common stock are sold under the program at a price of $1.82 per share pursuant to this prospectus
supplement, which was the last reported sale price of our common stock on The Nasdaq Capital Market on December 8, 2025, for aggregate
proceeds of $5.5 million after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate
dilution of $2.03 per share, representing a difference between our as adjusted net tangible book value per share as of September 30, 2025
after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options or warrants may result
in further dilution of your investment. See the section entitled “Dilution” on page S-9 of this prospectus supplement for
a more detailed illustration of the dilution you would incur if you participate in this offering.

Management will have broad discretion as
to the use of the proceeds from this offering and may not use the proceeds effectively.

Because we have not designated
the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion as to the
application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering.
Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value.

Future sales of substantial amounts of our
common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.

We may issue up to $5.69 million
of common stock from time to time in this offering. The issuance from time to time of shares in this offering, as well as our ability
to issue such shares in this offering, could have the effect of depressing the market price or increasing the market price volatility
of our common stock. This could impair our ability to raise capital through the sale of additional equity securities.

It is not possible to predict the actual
number of shares we will sell under the sales agreement, or the gross proceeds resulting from those sales.

Subject to certain limitations
in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Lead Agent at any
time throughout the term of the sales agreement. The number of shares that are sold through the Lead Agent after delivering a placement
notice will fluctuate based on a number of factors, including the market price of the common stock during the sales period, the limits
we set with the Lead Agent in any applicable placement notice, and the demand for our common stock during the sales period. Because the
price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the number of shares
that will be sold or the gross proceeds to be raised in connection with those sales. Further, we are not obligated to sell any shares
under the sales agreement, so you should not invest in our securities in reliance on the fact that we will actually raise new capital
via the at the market sales program covered by this prospectus supplement.

The common stock offered hereby will be
sold in an “at the market offering,” and investors who buy shares at different times will likely pay different prices.

Investors who purchase shares
in this offering at different times will likely pay different prices, and so may experience different levels of dilution and different
outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares
sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience
a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.

USE OF PROCEEDS

We may issue and sell
shares of common stock having aggregate sales proceeds of up to $5.5 million from time to time, after deducting sales agent
commissions and expenses. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold
and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully
utilize the sales agreement with the sales agents. We intend to use the net proceeds of this offering, if any, for working capital
and other general corporate purposes, which may include funding acquisitions or investments in businesses or products that are
complementary to our own and reducing indebtedness.

However, the nature, amounts
and timing of our actual expenditures may vary significantly depending on numerous factors. For example, we may also elect to use proceeds
from this offering to acquire complimentary products or businesses, although we are not a party to any letters of intent or definitive
agreements for any such acquisition. As a result, our management has and will retain broad discretion over the allocation of the net proceeds
from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes, and we will have
broad discretion in the application of net proceeds from this offering.

Pending our use of the net
proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term,
investment-grade, interest-bearing instruments and U.S. government securities.

DILUTION

If you invest in our common
stock, your interest will be diluted immediately to the extent of the difference between the public offering price per share and the adjusted
net tangible book value per share of our common stock after this offering.

Our net tangible book value
on September 30, 2025 was approximately $(8.4 million), or $(0.75) per share. “Net tangible book value” is total assets minus
the sum of liabilities and intangible assets. “Net tangible book value per share” is net tangible book value divided by the
total number of shares outstanding.